NCT06370598View on ClinicalTrials.gov

Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

June 30, 2025

Conditions
Pneumonia, Ventilator-Associated
Interventions
BIOLOGICAL

TP-122A

Bacteriophage cocktail targeting Psa

Trial Locations (1)

Unknown

CH Nantes, Nantes

Sponsors

Collaborators (1)

VectorB2B
All Listed Sponsors
collaborator

VectorB2B

INDUSTRY

lead

Technophage, SA

INDUSTRY

NCT06370598 - Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia | Biotech Hunter | Biotech Hunter